GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic.

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressin ...

On December 19, 2024, the FDA removed tirzepatide injection from its shortage list after slightly over two years. Tirzepatide is the active ingredient of Eli Lilly’s Mounjaro and Zepbound, two ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy for 2025. Both conservative and risk-tolerant investors ...

Gift 5 articles to anyone you choose each month when you subscribe. Taxpayers would fund popular weight-loss drugs for people with severe obesity under a proposal from American pharmaceutical ...

So it’s not at all surprising to see Eli Health announce Hormometer, an at-home hormone-testing system that uses your spit and your smartphone’s camera to measure hormone levels. Like many at ...